Executive Bio
Executive Profile Hidden
Interview Transcript
Disclaimer: This interview is for informational purposes only and should not be relied upon as a basis for investment decisions. In Practise is an independent publisher and all opinions expressed by guests are solely their own opinions and do not reflect the opinion of In Practise.
This is a snippet of the transcript.to get full access.
Could you give me a two-minute crash course on the litigation between Veeva and IQVIA? How far back does this go, and how do you frame the issue?
Yes, that's a good question. I'll try to do my best not to take up too much time. CRM is what field sales reps use to track how much of a drug they were using, according to IQVIA data. Peter mentioned that the IQVIA lawsuit stated that while you can use your data for field sales reps, any other data derived, such as metadata or derivative data from the IQVIA data, cannot be used. For example, if you wanted to aggregate data and draw a connection, such as if a field sales rep called on a doctor five times and then you wanted to correlate the performance of the Rx with that to show trended graphs, IQVIA says no. That data does not belong to you; you cannot connect that data with rep activity. Those have to stay separate; they are firewalled. This is critically useful information for the reps to show that their activity had a direct impact, and I can marry that up together. No, you have to keep those separate.
Free Sample of 50+ Interviews
Sign up to test our content quality with a free sample of 50+ interviews.
Or contact sales for full access
Related Content

Veeva Systems Data Solutions vs IQVIA
Former Director of Product Management at Veeva

Dassault Systèmes: Medidata's Integration, Growth & Culture
Former SVP of Global Sales, Services and Enablement at Dassault Systèmes

NVIDIA: Life Sciences AI Partnerships & Technological Development
AI Executive at IQVIA

Medidata Rave EDC: Market Leadership in Oncology Clinical Trials
Current VP of Clinical Operations at Biotech Company
© 2024 In Practise. All rights reserved. This material is for informational purposes only and should not be considered as investment advice.